# US 2006/0154865 A1 · Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154865 A1
- Document ID: US20060154865A1
- Status: Published application
- Kind: A1
- Application number: 11/313,101
- Filed: 2005-12-20
- Published: 2006-07-13
- Earliest claimed: 2004-12-22
- Inventors: Beat Amrein; Stefan Foser; Kurt Lang; Friedrich Metzger; Joerg Regula; Andreas Schaubmar; Friederike Hesse; Klaus-Peter Kuenkele; Martin Lanzendoerfer
- Web page: https://patentgrep.com/patent/US20060154865A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

## Claims

### Claim 1

A conjugate comprising an IGF-I variant and poly(ethylene glycol), wherein the IGF-I variant has at least one amino acid alteration selected from the group consisting of alterations at amino acid positions 27, 37, 65, and 68 of the wild-type IGF-I amino acid sequence wherein one or more of amino acids selected from the group consisting of 37, 65, and 68 is lysine, wherein amino acid 27 is a polar amino acid but is not lysine, and wherein said poly(ethylene glycol) is conjugated to said IGF-I variant via one or more primary amino groups.

### Claim 2 (depends on 1)

A conjugate according to claim 1 wherein said poly(ethylene glycol) has an overall molecular weight of from 20 to 100 kDa.

### Claim 3 (depends on 1)

A conjugate according to claim 1 wherein said IGF-I variant is additionally conjugated to poly(ethylene glycol) at the N-terminal amino acid.

### Claim 4 (depends on 1)

A conjugate according to claim 1 wherein said IGF-I variant is conjugated to poly(ethylene glycol) at a member selected from the group consisting of lysine 65, lysine 68, and lysine 37 or is conjugated to poly(ethylene glycol) at both K65 and K68.

### Claim 5 (depends on 1)

A conjugate according to claim 1 wherein said IGF-I variant is selected from the group consisting of RRKK, RRRK, RRKR, and RKRR.

### Claim 6 (depends on 1)

A conjugate according to claim 1 wherein up to three amino acids at the N-terminus are truncated.

### Claim 7

An IGF-I variant selected from the group consisting of RRKK, RRRK, RRKR, and RKRR wherein up to three amino acids at the N-terminus are truncated.

### Claim 8 (depends on 1)

A conjugate according to claim 1 wherein the poly(ethylene glycol) group(s) is/are branched poly(ethylene glycol) group(s).

### Claim 9 (depends on 1)

A conjugate according to claim 1 wherein the poly(ethylene glycol) group(s) have an overall molecular weight of 20 kDa to 100 kDa.

### Claim 10

An IGF-I variant having at least one amino acid alteration selected from the group consisting of alterations at amino acid positions 27, 37, 65, and 68 of the wild-type IGF-I amino acid sequence wherein one or more of amino acids selected from the group consisting of 37, 65, and 68 is lysine, wherein amino acid 27 is a polar amino acid but is not lysine.

### Claim 11 (depends on 9)

A method for the preparation of a conjugate comprising an IGF-I variant and one or two poly(ethylene glycol) group(s), said poly(ethylene glycol) group(s) having an overall molecular weight of from about 20 to about 100 kDa, said method comprising reacting the IGF-intermediate of claim 9 with activated (polyethylene) glycol under conditions such that said (polyethylene) glycol will react with one or two primary lysine amino groups of said IGF-I variant.

### Claim 12 (depends on 11)

The method according to claim 11 further comprising reacting (polyethylene) glycol with said IGF-I intermediate via N-terminal amino group of said IGF-I intermediate to yield an IGF-I variant with poly(ethylene glycol) bound to both the N-terminal amino group and to one or two primary lysine, amino groups..

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a conjugate of claim 1 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

A method for the treatment of Alzheimer's Disease comprising administering to a patient in need thereof a therapeutically effective amount of a conjugate of claim 1.

### Claim 15

A composition comprising a conjugate comprising an IGF-I variant and poly(ethylene glycol), wherein the IGF-I variant has at least one amino acid alteration selected from the group consisting of alterations at amino acid positions 27, 37, 65, and 68 of the wild-type IGF-I amino acid sequence wherein one or more of amino acids selected from the group consisting of 37, 65, and 68 is lysine, wherein amino acid 27 is a polar amino acid but is not lysine, and wherein said poly(ethylene glycol) is conjugated to said IGF-I variant via one or more primary amino groups) and an IGF-I variant which is conjugated to poly(ethylene glycol) at its N-terminus.

### Claim 16

A pharmaceutical composition comprising a conjugate comprising an IGF-I variant and poly(ethylene glycol), wherein the IGF-I variant has at least one amino acid alteration selected from the group consisting of alterations at amino acid positions 27, 37, 65, and 68 of the wild-type IGF-I amino acid sequence wherein one or more of amino acids selected from the group consisting of 37, 65, and 68 is lysine, wherein amino acid 27 is a polar amino acid but is not lysine, and wherein said poly(ethylene glycol) is conjugated to said IGF-I variant via one or more primary amino groups, an IGF-I variant which is conjugated to poly(ethylene glycol) at its N-terminus, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 15)

A method for the treatment of Alzheimer's Disease comprising administering to a patient in need thereof a therapeutically effective amount of a composition of claims 15.

### Claim 18 (depends on 16)

A method for the treatment of Alzheimer's Disease comprising administering to a patient in need thereof a therapeutically effective amount of a composition of claims 16.
